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MORPHOLOWC CHAN*E OF ADRENAL CORTEX IN DISEASE
Stimulation of the adrenal cortex by the "stress" of illness is now taken
for granted. Numerous publications have described changes in adrenal
cortical histology in particular diseases, and at least one author' has
attempted a general study of the adrenal cortex in an autopsy population.
Even so little attention is paid the adrenal cortex in the average autopsy
performed by the average pathologist. This is partly because such attention
is relatively unrewarding. In spite of the numerous publications devoted
to adrenal cortical histology, few are sufficiently well defined with respect
to age, sex, race, and types and duration of disease present. Few provide
sufficiently detailed data to serve as a frame of reference for the pathologist.
They do not tell how much hypertrophy is to be expected in a given
clinical situation, or how much to be considered extraordinary, nor do
they tell when lipid depletion is the "normal" response, and when it is
noteworthy. This paper is an attempt to provide sufficient data to make
such assessment possible.
MATERIALS AND METHODS
During a 20-month period (November 1959 to July 1961), adrenals from all
autopsies were placed intact in 10 per cent formalin for later examination by the
author. After fixation, the adrenals were carefully cleaned of adherent fat, blotted
dry, weighed,** and sectioned at approximately two to three mm. intervals. Two to
eight blocks from each adrenal pair were selected for microscopic examination. Routine
sections were stained with haemotoxylin and eosin (H and E). Adrenals from cirrhotic
patients with ascites and from 50 other randomly selected cases were also stained with
Wilder's reticulum stain.
The 407 consecutive autopsies performed during this 20-month period provided 335
pairs of adrenals suitable for accurate weighing. Seventy-two pairs were excluded for
the reasons shown in Table 1. However, material from some of these excluded cases
*Associate Pathologist, Danbury Hospital, Attending Pathologist, Veterans Admin-
istration Hospital, West Haven, and Instructor in Pathology, Yale University School
of Medicine.
** Fixed weight does not differ significantly from fresh weight.18
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was available for microscopic examination. Clinical data were obtained by a review of
the patients' records and were supplemented by pathological observations.
Adrenal sections were examined by the author without knowledge of the clinical or
other autopsy data. The cortices were measured with a millimeter ruler. The presence
of the zona glomerulosa was noted, and its extent was graded on a scale of zero to
three-plus. Both H and E, and reticulum-stained sections were used for this purpose.
The extent of lipid depletion in the fasciculata-reticularis of the H and E stained
sections was graded on a scale of zero to four-plus. A grade of zero was given to those
TABLE 1. GROUPS EXCLUDED FROM WEIGHT DATA
Total consecutive autopsies 407
Lost in processing 24
Excluded from weight data:
Female patients 2
Medial hemorrhage 2
Amyloid 1
Metastatic cancer 38
Previous adrenalectomy 1
Autopsy limited to head 4
Total not weighed 72
Remainder 335
TABLE 2. AccuRAnTLy WEIGHED GROUPS
Total accurately weighed 335
Negro patients 16
Steroid-treated patients 27
Nodular hyperplasia 16
Nonsteroid-treated white 276
males without nodular
hyperplasia
glands without lipid depletion in any zone, one and two-plus grades constituted lipid
depletion of zona reticularis and inner fasciculata, three-plus when depletion extended
to the middle of the fasciculata, and four-plus when the entire thickness from reticularis
to outer fasciculata was lipid depleted. These data were then correlated with inde-
pendently obtained clinical data.
A control population (Table 2) was selected from the carefully weighed pairs by
excluding adrenals from Negro patients, steroid-treated patients (all patients receiving
steroids for more than one week) and adrenals containing large cortical nodules
(nodular hyperplasia) (Fig. 3, adrenal 6). The remaining 276 adrenal pairs were
considered the control population (i.e., nonsteroid-treated white males without nodular
hyperplasia).
Subgroups of the control population were selected to test associations between
adrenal weight and a particular type of disease. Some of the subgroups were selected
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because of previous reports that adrenal hyperplasia and hyperfunction were associated
with carcinoma"5 and particularly with bronchogenic carcinoma,"'2 that adrenal
hyperplasia was associated with hypertension2' 8," and arteriosclerosis,2' and that
adrenal hypofunction was found in liver disease."2'
In analyzing the influence of disease on adrenal weight, patients were counted in
only one group even though they might have qualified for more than one group by
virtue of having more than one major disease. Thus all patients with cancer were
selected first, then patients with hypertension, liver disease, chronic pulmonary disease,
and severe arteriosclerosis (e.g., myocardial infarction and cerebral infarction), in that
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FIG. 1. Distribution of paired adrenal weights in grams plotted on semi-log paper.
order. This order was chosen after inspection of the data showed the larger glands
occurring more frequently in the first two groups.
While changes in adrenal weight reflect both duration of underlying disease and
intensity of the stimulating or inhibiting effects, changes in cortical lipid content
reflect morbid events during the few days preceding death. Therefore subgroups of
the control population selected to compare lipid content are based mainly on pre-
terminal events and differ from the weight groups.
Still a third grouping is necessary for consideration of the zona glomerulosa.
Increased aldosterone is known to occur in some cases of hypertension and cirrhosis
but not in cancer. Thus the presence of cancer in a patient with hypertension is
assumed to have little effect on the cortical zonation and for the purposes of this
analysis such an individual is grouped with the hypertensives.
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TABLE 3. FOURFOLD TABLES USED IN CHI SQUARE TESTS
A. Comparison of adrenals weighing less than 7 gm. in steroid-treated and untreated
groups.
<7.0 gm. >7.0 gm. Totals
No steroids 1 275 276
Steroids 4 23 27
Totals 5 298 303
(Chi square = 23; p > .01)
B. Comparison of adrenal pairs exceeding 22.1 gm. in cancer and noncancer groups.
<22.1 gm. >22.1 gm. Totals
Cancer 152* 7 159
No cancer 155 0 155
Totals 307 7 314
(Chi square = 5.1; p = .05)
C. Comparison of adrenal pairs exceeding 22.1 gm. in bronchogenic cancer and other
cancer groups.
<22.1 gm. >22.1 gm. Totals
Ca. lung 48* 4 52
Ca. other 105* 3 108
Totals 153 7 160
(CChi square = 1.1; not significant)
D. Comparison of incidence of arteriosclerotic heart disease (AHD) in patients over
60 with and without nodular hyperplasia of adrenal cortex.
Nod. hyp. No nod. hyp. Totals
AHD 10 82 92
No AHD 5 114 119
Totals 15 196 211
(Chi square = 2.4; not significant)
E. Comparison of incidence of hypertension in patients over 60 with and without
nodular hyperplasia.**
Nod. hyp. No nod. hyp. Totals
Hypertension 5 29 34
No hypertension 9 167 176
Totals 14 196 210
(Chi square = 2.82; not significant)
F. Comparison of incidence of nodular hyperplasia in patients 60 yrs. and older with
those younger than 60.
Nod. hyp. No nod. hyp. Totals
60 yrs. & older 14 210 224
Under 60 2 93 95
Totals 16 303 319
(Chi square = 1.8; not significant)
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TABLE 3 (Continued)
G. 1. Comparison of zona glomerulosa in patients with and without chronic pulmonary
disease (CPD).
Grade CPD Other Totals
2to3 5 50 55
0 to 1 22 246 268
Totals 27 296 323
(Chi square = <1; not significant)
2. Comparison of zona glomerulosa in patients with and without hypertension.*
Grade Hypertension Other Totals
2 to 3 9 46 55
Oto 1 19 249 268
Totals 28 295 323
(Chi square = <1; not significant)
3. Comparison of zona glomerulosa in patients with and without cirrhosis.
Grade Cirrhosis Other Totals
2 to 3 5 50 55
Oto 1 10 258 268
Totals 15 308 323
(Chi square = 1.8; not significant)
* Includes 38 adrenal pairs with gross metastases.
** All hypertensives were included whether or not cancer was present; thus more
are counted than in the weight data.
Statistical methods
A lognormal distribution curve was obtained by plotting frequency on the ordinate
against paired adrenal weights grouped to the nearest gram on the abscissa of semi-log
paper (Fig. 1). Calculations of mean and standard deviations and statistical analyses
were performed with the logarithms of the adrenal weights rather than with the weights
themselves. The standard t test for comparison of meansS' was used to test separately
the significance of the differences between the control group mean and the means
of the steroid-treated and Negro groups. Heterogeneity within the control group was
examined by an analysis of variance.' Subgroups were also compared by means of the
chi-square test using the Yates correction." The four-place tables used in making
these comparisons are shown in Table 3.
RESULTS AND DISCUSSION
ADRENAL WEIGHT
Arithmetic distribution curves of weight are skewed; however, the
logarithms of the weights are "normally" distributed and the usual
statistical methods of determining the mean and standard deviation can
be applied to the logarithms themselves." Such a distribution is called
lognormal, and the antilog of the mean so obtained is the geometric mean.
Figure 1 shows the lognormal distribution of the control population.
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Table 4 shows the mean weights and the standard deviations of the various
groups. The differences between the mean weights of the control group
and the steroid-treated and Negro groups are significant (p>.001 in each
instance). A significantly lighter mean weight is expected in the steroid-
treated group since exogenous steroids suppress endogenous ACTH,
thereby producing adrenal atrophy.8' Support for this result comes from
comparison of the number of adrenals weighing less than seven grams
TABLE 4. SUMMARY OF STATISTICAL DATA
Group N* X** log x SDt Range two SD
Control 276 12.9 1.1109 0.1174 7.5 - 22.1
Ca excluding lung 95 13.2 1.1202 0.1256 7.4 - 23.5
Ca lung 27 14.1 1.1489 0.1479 7.3 - 27.8
Hypertension 21 14.5 1.1522 0.0910 9.6 - 22.4
Chronic PD4 27 12.6 1.1011 0.1090 7.6 - 20.9
Liver disease 14 11.3 1.0513 0.0924 7.4 - 17.2
G A S ¶ 28 12.8 1.1070 0.0864 8.6 - 19.0
Misc. 64 12.8 1.1069 0.1168 7.5 - 21.9
Negro 16 10.4 1.0174 0.0927 6.8 - 13.2
Steroid R, 27 10.6 1.0230 0.1204 6.1 - 13.4
* N = number of adrenal pairs.
** x = mean weight.
t SD s Standard deviation.
4 Pulmonary disease.
¶ Generalized arteriosclerosis.
in the control and steroid-treated groups by means of the chi-square test
(Table 3, A). The result p>.Ol indicates more adrenal pairs weighing
less than two standard deviations in the steroid group than would be
expected by chance. Negro adrenals were originally excluded from the
control group because a lower mean weight for this group has been re-
ported.'M The above results are consistant with this finding. These con-
clusions assume that the control group is large enough to provide valid
values for the mean weight and standard deviation, and that the dis-
tribution of disease in the three main groups is random enough so that
the differences noted are due to steroid therapy in one group and race in
the other, and not to an increased frequency of a particular disease. Tables
5 and 6 give the appropriate data for the two groups.
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TABLE 5. STEROID-TREATED WHITE MALES
Disease
Total
amount Num-
re- ber Adre- Date
Body Type ceived days nal last Date
Age weight steroid (mg.) given weight dose death
A59-249 subacute myelogenous
leukemia
A60-73 acute bronchial asthma,
status
A60-111 bronchogenic Ca, hyper-
calcemia, emphysema
A60-131 decompensated Laennec's
cirrhosis
A60-138 chronic lymphatic
leukemia
A60-147 subacute hepatic necrosis
A60-173 subacute glomerular
nephritis with
nephrotic syndrome
A60-189 scleroderma
A60-197 multiple myeloma
A60-199 Hodgkin's disease
A60-207 bronchogenic Ca
hypercalcemia
A61-5 regional ileitis, staphylo-
coccal septicemia
31 -* prednisone
51 117 prednisone
66 109 prednisone
36 160 prednisone
decadron
61 - decadron
71 - prednisone
37 170 decadron
prednisone
47 125 metacortin
64 162 decadron
65 155 cortisone
41 - prednisone
29 - metacortin
2063 21 13.7
635 20 6.6
900 15 13.5
450 30 10.0
18 3
116 27 12.2
2075 49 9.0
84 7 16.5
630 14
1600 40 11.5
21 28 13.0
1800 18 11.1
705 19 11.5
3340 82 9.0
A61-8 staphylococcal pneumo- 66 150 prednisone 43 10 14.0
nitis, hypertension, diabetes
A61-11 Ca prostate with osteo- 68 - metacortin 1270 57 16.5
blastic metastases
A61-28 rheumatoid arthritis 65 - prednisone 7300 365 6.6
aspiration pneumonitis
abscess
A61-72 myelofibrosis, acute 57 155 prednisone 1260 29 13.5
blastic leukemia
A61-74 pemphigus, arteriosclerotic 74 105 prednisone 3700 37 8.9
heart disease ACTH (40u) 160 4
A61-97 chronic myelogenous 29 180 prednisone 260 10 8.7
leukemia
* Not recorded.
Autopsy
no.
12/28 12/28
4/21 4/21
7/7 7/7
8/11 8/11
8/22 8/23
9/4 9/5
9/11 10/16
2/9
12/1
12/1
12/9
10/20
1960
1/10
11/15
12/1
12/1
12/16
1/5
1961
1/10
1/14 1/14
1/19 2/4
3/29 3/29
3/14 3/29
3/18 - 3/19
4/27 4/27
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TABLE 5. (Continued)
Autopsy
no. Disease
A61-113 sarcoidosis, renal lithiasis
pyelonephritis
A61-126 hemolyticanemia,staphy-
lococcal pneumonitis
diabetes
A61-128 tuberculosis, vasculitis
amputation, pulmonary
emboli
A61-136 idiopathic cardiomegaly
A60-143 subacute hepatic necrosis
A59-246 Ca bladder, pyelonephritis
A60-53 mitral stenosis
A60-61 rheumatoid arthritis
necrosis femoral heads
bacteroides septicemia
pulmonary asbestosis
A61-64 tuberculosis
Hodgkin's disease
** Cachectic.
Body Type
Age weight steroid
45 95 decadron
65 180 prednisone
42 110 metacortin
50
64
54
140 prednisone
- prednisone
182 prednisone
51 C** prednisone
68 C prednisone
69 C metacortin
Total
amount Num-
re- ber Adre- Date
ceived days nal last
(mg.) given weight dose
6837 477 6.0 12/1
1960
1750 20 8.0 6/2
1600 16 10.0 6/2
500
1500
720
1580 50
16000 1095
13 10.5
37 6.5
13 13.7
9.0
12.8
Date
death
5/18
1961
6/2
6/4
6/5 6/19
7/1 7/2
12/19 12/19
3/25 3/27
8/4 4/8
1957 1960
360 9 12.3 3/17 3/17
A similar comparison between the subgroups means (Table 4) and
the control mean is not valid. The subgroup means could be compared
one with another or their total variance analyzed to determine the likeli-
hood of their being drawn by chance from a single population. The latter
analyses yielded p = .05, suggesting that some of the differences noted
are not simply chance.
Adrenal pairs exceeding a weight of plus two standard deviations from
the mean (22.1 grams) occurred only in patients with carcinoma. This
distribution was tested with the chi-square technique (Table 3, B) and
found significant (p = .05). The incidence of heavy adrenals in patients
with bronchogenic carcinoma was compared to that in patients with other
types of malignancy (Table 3, C.). A significant difference was not
found.
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The preceding statistical comparisons also assume a random distribution
of age and body weight. In fact, age and body weight show little correlation
with adrenal weight. Table 7 shows no correlation of adrenal weight and
age, with the possible exception of the oldest age group where a tendency
toward lighter adrenals is noted. A recent study' has demonstrated
decreased cortisol metabolism by liver and impaired renal excretion of
TABLE 6. NEGRO PATIENTS
Age
63
58
41
37
65
41
Body weight
133
136
130
163
116
C*
Blood
pressure
180/100
160/85
210/120
300/140
120/80
140/70
64 150 210/110
67 -** 150/80
65 C 110/70
73 - 110/70
60 185 140/80
69 C 120/80
73 160 170/90
27 190 220/110
66 180 180/90
76 139 110/70
Adrenal
weight
13.0
9.0
8.3
14.6
10.5
14.0
11.3
7.0
8.2
10.2
9.8
8.7
12.0
10.5
9.5
13.5
Disease
Ca pancreas
Ca lung
Hypertension
Hypertension
Tuberculosis
Multiple sclero-
sis, osteomyelitis
Hypertension
Bronchitis, em-
physema
Ca prostate
Reticulum cell
sarcoma
Tuberculosis
Ca lung
Acute pulmonary
embolism
Glomerulo-
nephritis
Ca bile duct
Emphysema
* Cachectic.
** Not recorded.
cortisol with advancing age. Endogenous ACTH secretion would be
reduced and some adrenal atrophy would be expected.
Table 8 shows no correlation between adrenal weight and body weight,
with the possible exception of the largest individuals. This comparison is
not too reliable because of the rapid weight loss induced by disease.
Atrophic adrenals, not steroid-induced, were usually associated with
extreme cachexia.
Table 9 relates adrenal weight to cortical thickness. Cortical thickness
has been used as the criterion of hyperplasia in two recent studies.'-'2
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A59-241
A60-21
A60-81
A60-89
A60-92
A60-116
A60-169
A60-195
A60-210
A61-20
A61-22
A61-26
A61-75
A61-89
A61-96
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CORTICAL ZONATION AND LIPID CONTENT
The adrenal cortex is described as having three zones: an outer zona
glomerulosa, a middle zona fasciculata, and an inner zona reticularis.
Recently, Symingtone convincingly showed that under the stimulus of
TABLE 7. VARIATION OF ADRENAL WEIGHT WITH AGE
Adrenal weight (grams)
Total Average 24- 22- 20- 18- 16- 14- 12- 10- 8- 6- Age in
individuals weight >26 25.9 23.9 21.9 19.9 17.9 15.9 13.9 11.9 9.9 7.9 years
3 17.0 1 1 1 20-29
18 13.2 1 1 6 3 5 2 30-39
42 14.7 1 2 4 3 11 11 8 2 40-49
28 13.9 2 3 4 7 2 7 1 2 50-59
126 13.5 1 2 3 5 5 5 72 7 30 17 4 60-69
58 12.7 1 1 1 3 11 11 16 13 1 >70
TABLE 8. VARIATIONS OF ADRENAL WEIGHT WITH BODY WEIGHT
Adrenal weight (grams)
Body
Total Average 24- 22- 20- 18- 16- 14- 12- 10- 8- 6- weight
individuals weight >26 25.9 23.9 21.9 19.9 17.9 15.9 13.9 11.9 9.9 7.9 (Ibs)
56 12.6 1 1 2 4 9 10 16 10 3 Cachectic*
8 13.0 1 2 3 2 80-99
25 11.8 1 1 2 8 3 9 1 100-119
37 15.0 1 1 4 2 4 6 9 8 2 120-139
35 13.0 1 2 1 2 5 8 8 6 2 140-159
30 14.2 1 3 3 11 3 6 2 1 160-179
18 14.2 2 1 1 6 2 4 2 180-199
17 15.1 1 1 2 6 4 3 >200
* Only description available.
ACTH, the lipid-laden cells of the fasciculata become transformed into
lipid-poor, RNA-rich cells identical with those in the zona reticularis.
Thus, the middle and inner zones represent the same cells in different
degrees of activity. The subcapsular zone, zona glomerulosa, has been
shown to produce aldosterone in the ox,' and to vary in thickness in re-
sponse to body electrolyte changes in the rat.' In the ox, rat, and dog
the zona glomerulosa is well defined, but in man it is a poorly defined
zone which varies from place to place and from individual to individual,
merging imperceptibly with the outer fasciculata.'-' Even so, in man,
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histologic changes in this zone have been correlated with serum electro-
lyte imbalance and hypertension.'9
` One author has attempted to cor-
relate the outer fasciculata rather than the glomerulosa with aldosterone
production.' Reticulum stain has been suggested as a valuable method
of identifying the zona glomerulosa."'
In the present study precise measurements were not attempted because
of the large series and inherent variability of the zona glomerulosa.
Instead, the subcapsular zone was appraised for distinctness and extent,
and graded on a scale of zero to three-plus. Repeat appraisal of 40
randomly selected cases after a lapse of three years showed agreement
in 31 cases (77%o). Reticulum stain did not facilitate grading.
TABLE 9. CORRESPONDENCE OF ADRENAL WEIGHT AND CORTICAL THICKNESS
Adrenal weight (grams)
Cortical thickness 6-8 8.1- 10.1- 12.1 14.1- 16.1- 18.1- 20.1- 22.1- 24.1- 26.1-
mM. 10 12 14 16 18 20 22 24 26 30 Totals
2.0-3.0 3 1 2 5 5 4 1 3 24
1.6-1.9 1 2 1 3 4 1 12
1.3-1.5 8 11 19 24 6 3 2 71
1.0-1.2 5 21 38 41 23 2 3 1 1 133
0.8-0.9 7 9 15 5 3 1 39
0.6-0.7 6 14 5 1 26
Totals 18 53 69 71 52 14 15 9 4 2 3 310
The majority of glands (268 of 323) were graded zero to one-plus.
Six pairs were graded three-plus and 49 were two-plus. Electrolyte data
was available for two patients in the three-plus group. One of these, a
cirrhotic, had hyponatremia during the week preceding death. The other,
with cor pulmonale and emphysema, had normal electrolytes five days
prior to death. Of the remaining four cases graded three-plus, one had
cirrhosis, one septicemia, and two carcinoma (lung and sinus). Electro-
lytes were available for 17 of the 49 cases graded two-plus. Only two of
these had hyponatremia.
The grade two-plus and three-plus groups were combined for statistical
analysis. Among these 55 cases were nine hypertensives and five cirrhotics.
Chi-square analysis (Table 3G) does not show a statistically significant
incidence for any group tested.
The work of Symingtone provides the pathologist with a guide to
the evaluation of ACTH function based on the extent of cortical lipid
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depletion. Figure 2 shows the extent of lipid depletion in various sub-
groups of the control population. The total number of individuals in
these subgroups differs from the total used to establish mean weight.
In choosing these categories, the preterminal events were considered of
Amount of Lipid Depletion
Subgrolup Percent
number of OtQ 1+ 2+ 3 to 4+ of
individuols subgroup
PUlmonary 78
insufficiency 27F]_
Decomp nsated 64
cirrhosis
14 21
'4
Myocardialx 72
infarction
ie Ii I- 21 1 J. ~~~0
Sepsisx- 82
Seplis
on steroids
8 5 m 0 1~~~~~ 26
3 see table XVfor duration of sympos
xx see table XVI for sourae of sepsis
FIG. 2. Patterns of lipid depletion associated with the various disease categories.
greater significance than the underlying disease. Thus most patients with
hypertension died from myocardial infarction or cerebrovascular accidents
and were so classified. Sections were available from some adrenals not
suitable for weighing and vice versa. Categories with the least depletion
were cirrhosis, pulmonary insufficiency, and myocardial infarction.
Patients with severe sepsis showed the most marked lipid depletion.
Pseudotubule formation was frequently observed in completely depleted
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glands, and a few showed focal infarction and necrosis. The two cases
excluded because of massive intramedullary hemorrhage were also cases
of severe sepsis. The significance of these observations is discussed in sub-
sequent sections.
LIPID DEPLETION IN RESPONSE TO INFECTION
Lipid depletion in response to severe acute bacterial infection was an
early and frequent observation."' Occasionally, in addition to lipid
depletion, degenerative changes (focal necrosis and pseudotubule for-
mation) are seen. Hemorrhagic cortical necrosis is an extreme form of
degeneration associated with gram-negative septicemia and particularly
meningococcemia. ' Berry and Smythe7 suggest that small amounts of
endotoxin stimulate the adrenal cortex, but large amounts are toxic
to it. More recently, attempts have been made to characterize this response
to sepsis. Nadel, et al,' compared the effects of ACTH and endotoxin,
and found that both increased excretion of three polar corticosteroids,
(6 (B)-hydroxycortisol, 2(a)hydroxycortisol, and cortisol) in vivo. How-
ever, Glenchur and Doe' measured plasma and urine 17-hydroxycorticos-
teroids in seven patients with bacterial pneumonia and found elevated
plasma levels but decreased urine levels. The half-life of exogenous cortisol
was increased. The authors suggest four possible mechanisms to explain
their findings: abnormal hepatic conjugation, renal retention of conjugates,
increased plasma protein binding, and increased conversion of cortisol
to 20-hydroxy forms.
The foregoing suggests that chronic sepsis would lead to adrenal hyper-
trophy, and this may be one of the stimuli to adrenal hyperplasia in some
cancer patients whose long illnesses are complicated by repeated or
persistent sepsis.
EFFECT OF STEROID TREATMENT
The earliest and most consistent effect of steroid treatment is decreased
lipid depletion.e' While prolonged steroid administration leads to cortical
atrophy, this is presumably a reflection of endogenous ACTH suppression
by the exogenous steroid. Extreme atrophy (less than 7.0 grams) occurred
in four steroid-treated individuals. Two of these (cases A60-73 and A61-
28, see Table 5) received steroids continuously for at least one year.
Case A60-143, subacute hepatic necrosis, received 1,500 mg. of prednisone
over a 37-day interval. The severe liver damage may have potentiated
the steroid effect. Case A60-73 received only 635 mg. of prednisone over
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a 20-day interval, and died in status asthmaticus during the first night
of reduced dosage. The combined adrenal weight of 6.6 grams would
seem to be an inordinate amount of atrophy for a relatively short period
of treatment. This patient's adrenal atrophy may have preceded treat-
ment and may have been related to the late and sudden onset of severe
asthma.'
TABLE 10. CANCER ASSOCIATED WITH ADRENAL HYPERPLASIA
Clinical Cushing's
Type cancer Adrenal weight syndrome
Oat cell Ca lung 29.0 Yes
Oat cell Ca lung* 39.0 Yes
Epidermoid Ca mouth 25.0 No
Adeno Ca rectum 29.0 No
Epidermoid Ca lung 27.5 No
Epidermoid Ca lung 22.9 No
Undifferentiated, probably
pancreas 23.0 No
Adeno Ca lung 24.0 No
* These adrenals were examined after completion of data collection for this paper
and are not included in other weight calculations.
ADRENAL RESPONSE TO CARCINOMA
Fulminant Cushing's syndrome in association with "non-endocrine" car-
cinoma is a well-established clinical entity. These cases are summarized in
several recent reviews.6" The adrenal hyperplasia and hyperfunction
is stimulated by ACTH-like peptides produced by the cancer. The
general or specific nature of this phenomenon is still in question. Several
recent studies of blood and urine steroid levels in patients with bron-
chogenic carcinoma have shown elevated baseline steroid levels and hyper-
responsiveness to ACTH when compared to a variety of control groups.8'
'
Other authors have attempted to demonstrate anatomic evidence of
adrenal hyperplasia in patients dying of bronchogenice0 and other types
of carcinoma.' It can be seen from Table 4 that the mean adrenal weight
for patients with bronchogenic carcinoma was slightly higher than other
nonhypertensive groups. Both carcinoma groups show greater deviation
from the mean than other groups. All of the adrenals exceeding plus-two
standard deviations from the control mean were associated with car-
cinoma (Table 10). These data support the suggestion that cancer is
occasionally associated with adrenal hyperplasia. However, the frequency
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1. S62-1958, 12.4 gins., nornal.
2. A61-30, 29.0 gins., diffuse hyperplasia, carcinoma of the rectum.
3. A61-66, 27.5 gins., diffuse hyperplasia, epidermoid carcinoma lung.
4. S61-354, 39.0 gins., diffuse hyperplasia, oat cell carcinoma lung,
Cushing's syndrome.
5. A60-22, 29.0 gins., diffuse hyperplasia, oat cell carcinoma lung,
Cushing's syndrome.
6 A61-19, 21.3 gmns., nodular hyperplasia.
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of hyperplasia was similar in bronchogenic and nonbronchogenic car-
cinoma. Only one patient with large adrenals had clinical evidence of
Cushing's syndrome. The adrenals of this patient with oat cell carcinoma
showed a distinctive morphology.' A second patient with oat cell carcinoma
and Cushing's syndrome (Table 10) was studied after completion of data
TABLE 11. HYPERTENSIVE PATIENTS
Blood pressure
190/110
210/110
Cardiomegaly (>700 gins)
200/90
210/140
200/150
175/120
200/120
210/95
180/100
230/110
240/120
160/110
180/120
210/120
Cardiomegaly (>700 gms)
240/160
250/150
230/125
220/120
220/120
Terminal event
MI
MI
Uremia
MI
MI
MI
MI
CVA**
CVA
Peritonitis
MI
MI
CHFt
CHF
MI
CVA
CVA
CVA
CVA
MI
* MI = myocardial infarction.
** CVA = cerebrovascular accident.
t CHF = congestive heart failure.
collection. Both cases showed a uniform hypertrophy of the adrenal
cortex which was composed of large polygonal eosinophilic cells, pre-
sumably an exaggerated ACTH response. The hyperplastic adrenal cortices
from patients with carcinoma but without Cushing's syndrome were com-
posed of smaller cells often containing abundant lipid (Figs. 3 and 4).
Marks, et al,' studied a patient with carcinoma, large adrenals, and
ACTH hyper-responsiveness but without Cushing's syndrome. He pos-
tulated production of an adrenal weight-maintaining factor distinct from
ACTH. If this is so, tumors secreting such a factor, though uncommon,
45
Autopsy no.
A59-219
A59-233
A59-247
A60-12
A60-35
A60-55
A60-58
A60-64
A60-78
A60-104
A60-106
A60-113
A60-122
A60-170
A60-190
A60-203
A61-60
A61-79
A61-114
A61-135
A61-138YALE JOURNAL OF BIOLOGY AND MEDICINE
are less rare than those producing an ACTH-like material. In fact, only
four types of tumors have shown multiple instances of associated Cush-
ing's syndrome. These are oat cell carcinoma,"` islet cell carcinoma
(with and without insulin hypersecretion, but all occurring in women),"
bronchial adenoma of the carcinoid type with and without serotonin pro-
TABLE 12. PATIENTS WITH NODULAR HYPERPLASIA
Blood Adrenal Heart Degree of
Autopsy no. Age pressure weight weight arteriosclerosist
A59-228 71 140/80 20.0 400 MI
A59-250 56* 100/70 21.0 300 Mild
A59-251
A60-7
A60-44
A60-51
67 100/60
61 140/80
70 140/80
64 160/80
8.2
24.5
19.2
13.5
450 Severe
370 None
650 MI
350 None
A60-215 65 "high" 21.2 600 MI
A60-216
A61-19
A61-32
A61-34
82 190/90
62 220/110
68 160/80
61 110/70
A61-46 71 200/100
A61-56 67 130/90
A61-81 69 180/70
A61-112 72 120/70
A61-118 48* 120/70
10.8
21.3
17.5
25.0
600
400
350
350
MI
Mild
MI, CVA
MI
19.2 550 Infarct Of the
bowel
AHD, MI
28.5 600 MI
15.0 370 MI
23.0 200 None
Other
Tbc. renal adeno-
ma
Epidermoid Ca
Esophagus
Ca pancreas
Glioblastoma
On steroids
Multiple myeloma
Hypokalemic
alkalosis attrib-
uted to diuretics
Acute pancreatitis
Ca prostate
Paget's Disease
Ca cecum
Ca lung
* Under 55 not included in chi square statistics.
t Abbreviations used follow:
MI = Myocardial infarction.
CVA = Cerebrovascular accident.
AHD = Arteriosclerotic heart disease.
duction,"' l (a recent report notes this association with an abdominal
carcinoid),' and thymoma. The latter have shown an atypical histology,
having an organoid appearance somewhat like that of the bronchial
adenomas." ACTH-like material has so far only been extracted from oat
cell and islet cell carcinoma.' Therefore, while adrenal hyperplasia is oc-
casionally present in patients with a variety of carcinomas, Cushing's syn-
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drome is probably a specific association with only a few rare and pos-
sibly related types of tumor.
HYPERTENSION
Without nodular adrenals
The numerous studies of adrenal morphology in patients with hyper-
tension have produced conflicting results. Hyperplasia has been found by
TABLE 13. PATIENTS WITH PULMONARY INSUFFICIENCY*
c
Disease M
PE, old, multiple
tbc, E, CP
E, CP
E, CP
PE, old, multiple
E, CP
E, CP
E, CP
E, CP
E, CP
E, CP
E, CP
E, CP
E, CP
E, CP
tbc, E, CP
E, CP
E, CP
E, CP
tbc, E, CP
E, CP
E, CP
E, CP
E, CP, bleeding ulcer
tbc, PE
tbc, MI
tbc, E, CP, MI
100
per
nent
rBC
37
21
100
per
cent
'C
53
40
26 64
19 38
18 38
31 37
29 78
28 48
25 56
97-99 38-42 mm
per cent Hg
arterial arterial
Os PCOS
44 81
17 46
15 33
47
Autopsy
no. Age
A60-2 61
A59-212 62
A59-230 61
A59-229 62
A60-9 62
A60-18 69
A60-19 67
A60-119 81
A60-129 62
A60-140 46
A60-146 63
A60-191 74
A60-214 59
A60-217 50
A61-2 59
A61-9 66
A61-21 . .
A61-38 59
A61-49 65
A61-76 59
A61-83 75
A61-105 64
A61-120 63
A60-8 59
A60-162 70
A60-165 73
A60-196 46
Adrenal
weight
7.2
14.5
9.8
13.5
10.0
7.5
13.0
10.5
10.9
10.5
10.0
9.0
14.7
15.0
11.0
13.0
18.7
16.5
15.0
11.7
11.5
10.5
10.5
13.7
10.6
14.0
* Abbreviations follow:
MBC = Maximum breathing capacity. E = Emphysema.
VC = Vital capacity. CP = Cor pulmonale.
PE = Pulmonary emboli. MI = Myocardial infarction.
tbc = tuberculosis.TALE JOURNAL OF BIOLOGY AND MEDICINE
some"'14" and not by others." "' Micronodules were associated with hyper-
tension by some7' but not by others.m''' Several authors?-'"- have
observed glands from hypertension to be lipid-laden, and two authors'17
thought that cortical lipid actually increased.
In the present study hypertensives were selected on the basis of a well-
documented hypertensive history with diastolic blood pressures of 90 mm.
of Hg. or higher. Twenty-one patients met these criteria (Table 11).
Patients with hypertension secondary to primary renal disease were ex-
TABLE 14. ORIGIN OF GROSSLY VISIBLE METASTASES
Lung 25
Prostate 4
Lymphoma 2
Melanoma 1
Pancreas 1
Stomach 1
Testes 1
Esophagus 1
Hepatoma 1
Bladder 1
Total 38
cluded. Patients with nodular adrenals and hypertension are considered
in the next section. The mean weight for this group was slightly higher
than other groups (Table 4) and all but one had lipid-laden glands. Lack
of lipid depletion may be related to terminal events, since most died
suddenly from myocardial infarctions or cerebral accidents (Table 11).
Since most of the nodules removed from patients with primary aldos-
teronism have had a lipid-laden fascicular pattern, one author' has sug-
gested that lipid-rich adrenals from hypertensives may also be producing
excessive aldosterone. However, this same author and others1'X have also
suggested that this lipid-laden appearance of the adrenal cortex simply
reflects arteriolar disease in the adrenal capsule. Certainly a lipid-rich
cortex does not suggest excessive ACTH stimulation.
Nodular hyperplasia
Several authors have correlated nodular adrenals with hypertension
and arteriosclerosis.8"u'17.20.X X 4 Common features in these observations
were lipid-laden glands and elderly patients. While some authors have sug-
gested that nodular adrenals are related causally to hypertension7 and
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arteriosclerosis,"' others have considered the adrenal changes degenerative
secondary to arterial disease."
Clinical data from patients with nodular adrenals segregated in this
study are presented in Table 12. Of the 16 cases, only two were under 60.
Five had documented hypertension and ten had severe manifestations of
arteriosclerosis. None of these incidences is statistically significant when
tested by the chi-square technique (Table 3 D,E,F).
TABLE 15. AcuE MYOCARDIAL INFARCTION
Autopsy no.
A59-219
A59-226
A59-220
A59-225
A59-222
A59-247
A60-39
A60-58
A60-64
A60-72
A60-122
A60-151
A60-167
A60-188
A60-203
A60-208
A61-15
A61-141
Duration of symptoms
36 hours
24 hours
6 hours
<1 hour
10 hours
12 hours
1 week
1 week
72 hours
48 hours
6 hours
96 hours
24 hours
10 hours
12 hours
72 hours
No data available
24 hours
Shock
no
no
yes
no
yes
yes
no
no
no
no
no
no
no
no
yes
yes
no
CIRRHOSIS
Recent studies have shown impaired metabolism of hydrocortisone in
cirrhotic patients. The half-life of infused exogenous cortisol is doubled."
Since the miscible pool of cortisol is normal in these individuals, sup-
pression of endogenous ACTH and decreased cortical stimulation is
probable.' Both the weight and lipid depletion data obtained in this
study are consistent with ACTH suppression. The mean weight is less
than other nonsteroid-treated groups (Table 4) and relatively little lipid
depletion is noted (Fig. 2).
PULMONARY INSUFFICIENCY
Patients were placed in this group on the basis of clinical and autopsy
evidence of severe lung damage (e.g., emphysema, fibrosis, advanced tuber-
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culosis, and cor pulmonale). Available information on the extent of pul-
monary impairment during life is recorded in Table 13. The striking
feature in this group is lack of lipid depletion (Fig. 2). This is inter-
preted as lack of or diminished pituitary response to the stress of chronic
dyspnea. Normal plasma and urine levels of 170HCS and normal re-
sponsiveness to ACTH have been recorded in patients with chronic
pulmonary disease and dyspnea.'
TABLE 16. PATIENTS DYING WITH MAJOR SEPSIS
Autopsy no. Source Other
A59-213 Pelvic abscess 12 days post operative, sub-
total resection of bladder
A59-224 Aspiration pneumonia Ca lung metastatic to brain
A60-14 Pneumonia Parkinson's disease
A60-28 Pneumonia Multiple sclerosis
A60-37 Pneumionia
A60-80 Pyelonephritis Focal pancreatitis
Pneumonia
A60-82 Septicemia Chronic brain syndrome
A60-107 Septicemia Aplastic anemia
A60-200 Peritonitis Diverticulitis
A61-109 Peritonitis
A61-110 Pyelonephritis Neurogenic bladder
Pneumonia secondary to syphilis
Septiceniia
MISCELLANEOUS
Three cases of myelolipomata were encountered in this series. This
is higher than a previously reported incidence.' One unusual microscopic
metastasis was noted. This was metastatic Kaposi sarcoma in a patient
with Kaposi's sarcoma of limbs and bowel and adenocarcinoma of the
stomach. None of the adrenals containing metastases were completely
replaced, nor did any of the patients manifest adrenal insufficiency. A
breakdown of gross adrenal metastases is presented in Table 14.
SUMMARY
Morphologic observations made on 335 intact pairs of adrenal glands
obtained from 407 autopsies are correlated with clinical data.
Adrenal weight follows a lognormal distribution (geometric mean 12.9
gms., plus or minus 2 S.D., 7.5 gms. to 22.1 gms.). The geometric means
5o
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obtained from Negro patients and steroid-treated white patients were
significantly lower than the mean for white males not on steroids.
Comparison of adrenal weight with body weight and patient's age
showed little correlation except at the extremes of age and weight.
Adrenal weight correlated well with cortical thickness.
Adrenal pairs exceeding a weight of 22.1 gms. occurred only in patients
with carcinoma. Hyperplastic glands occurred with equal frequency in
bronchogenic and other types of malignancy. Two cases of Cushing's syn-
drome occurred in patients with oat cell carcinoma. Glands from these
individuals showed a quantitatively distinctive type of hypertrophy.
Cases with nodular hyperplasia were not included in weight data
but were analyzed separately. Nodular hyperplasia did not correlate
with age or disease.
Sections were graded with respect to the thickness of zona glomerulosa
and extent of lipid depletion in the fasciculata-reticularis. Variations in the
zona glomerulosa did not correlate with cirrhosis, hypertension, or renal
disease. Lipid depletion of the fasciculata-reticularis was most striking
in severe sepsis. Little cortical lipid depletion was seen in cases of decom-
pensated cirrhosis and pulmonary insufficiency. This may represent
diminished ACTH release in these "stressful" states.
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